The invention relates to novel compounds that are derivatives of 1, 4-benzodiazapin-2-one, having the general formula (I) and being limited to structural variants (1-6), on the condition that : а) structures 1 (R1=Br, R4=F), 3 (R1=OCF3, R4=Н), 5 (R1=NO2, R4=Cl) and 6 (R1=NO2, R4=F) have the following substituents R2 and R3 : - R2=Н, СН2СОСН3, СН2СООСН3, CH2CONHNH2; - R3=OAlk, NHAr, where Alk=С2Н5, С3Н7, С4Н9, (СН2)2ОН, (СН2)2ОСН3, (H2C); Ar=(R5) R5=о-, m-, р- СОСН3, Cl, F, Br, NO2, CF3; b) structure 2 (R1=Cl, R4=Н) has the following substituents R2 and R3 : if R2=Н, then R3=OAlk, NHAr, where Alk=(СН2)2ОСН3, (H2C); Ar=(R5) R5=m-, р- СОСН3, o-, m-, p-F, Br, CF3; if R2=СН2СОСН3, СН2СООСН3, CH2CONHNH2, then R3=OAlk, NHAr, where Alk=С2Н5, С3Н7, С4Н9, (СН2)2ОН, (СН2)2ОСН3, (H2C); Ar=(R5) R5=о-, m-, р- СОСН3, Cl, F, Br, NO2, CF3; c) structure 4 (R1=NO2, R4=Н) has the following substituents R2 and R3 : if R2=Н, then R3=OAlk, NHAr, where Alk=(CH2)2OCH3, (H2C); Ar=(R5) R5=о-, m-, р- СОСН3, Cl, F, Br, NO2, CF3; if R2=СН2СОСН3, СН2СООСН3, CH2CONHNH2, then R3=OAlk, NHAr, where Alk=С2Н5, С3Н7, С4Н9, (СН2)2ОН, (СН2)2ОСН3, (H2C); Ar=(R5) R5=о-, m-, р- СОСН3, Cl, F, Br, NO2, CF3, and the use of said compounds in the field of medicine as analgesics, anorexigenic or orexigenic agents for weight loss and weight gain respectively, antidepressants and anxiolytics for treating psychological disorders, and also antihypoxic and nootropic agents for the prophylaxis and treatment of central nervous system disorders.